立体定向磁共振引导在线自适应放疗(SMART)治疗交界可切除和局部晚期胰腺癌:多中心、开放标签2期研究
这项前瞻性多中心单臂开放标签2期试验纳入136例经≥3个月化疗后无远处进展且CA19-9≤500 U/mL的交界可切除或局部晚期胰腺癌患者,给予50 Gy/5次(BED10=100 Gy)的SMART。诊断起2年OS为53.6%,SMART起2年OS为40.5%;明确、很可能、可能归因于SMART的晚期≥3级毒性分别为0%、4.6%、11.5%。
要点
- SMART处方50 Gy/5次(BED10=100 Gy),34.6%患者放疗后接受手术。
- 诊断起2年OS为53.6%,SMART起2年OS为40.5%。
- 明确、很可能、可能归因于SMART的晚期≥3级毒性分别为0%、4.6%、11.5%。
核心结论
- 2期SMART试验的长期结果显示出令人鼓舞的OS和有限的严重毒性,作者认为需要对这一新策略进行额外的前瞻性评估。
研究设计与样本
- 前瞻性、多中心、单臂、开放标签2期试验(NCT03621644),纳入136例患者(局部晚期胰腺癌56.6%,交界可切除胰腺癌43.4%)。
- 入组条件为接受任何化疗≥3个月后无远处进展且CA19-9≤500 U/mL。
- SMART在0.35 T磁共振引导系统上实施,处方剂量50 Gy分5次(BED10=100 Gy),选择性覆盖为可选。
- SMART后允许手术和化疗。
主要发现
- 平均年龄65.7岁(范围36-85岁),诱导FOLFIRINOX常见(81.7%),多数接受选择性覆盖(57.4%),34.6%在SMART后接受手术。
- 中位随访自诊断起22.9个月、自SMART起14.2个月。
- 自诊断起2年OS为53.6%,自SMART起2年OS为40.5%。
- 明确、很可能、可能归因于SMART的晚期≥3级毒性分别见于0%、4.6%、11.5%的患者。
关键数值与推荐
- SMART处方剂量为50 Gy分5次,BED10=100 Gy。
- 入组要求化疗≥3个月后无远处进展且CA19-9≤500 U/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要对这一新策略进行额外的前瞻性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Radiation dose escalation may improve local control (LC) and overall survival (OS) in select pancreatic ductal adenocarcinoma (PDAC) patients. We prospectively evaluated the safety and efficacy of ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) for borderline resectable (BRPC) and locally advanced pancreas cancer (LAPC). The primary endpoint of acute grade ≥ 3 gastrointestinal (GI) toxicity definitely related to SMART was previously published with median follow-up (FU) 8.8 months from SMART. We now present more mature outcomes including OS and late toxicity. MATERIALS AND METHODS: This prospective, multi-center, single-arm open-label phase 2 trial (NCT03621644) enrolled 136 patients (LAPC 56.6 %; BRPC 43.4 %) after ≥ 3 months of any chemotherapy without distant progression and CA19-9 ≤ 500 U/mL. SMART was delivered on a 0.35 T MR-guided system prescribed to 50 Gy in 5 fractions (biologically effective dose10 [BED10] = 100 Gy). Elective coverage was optional. Surgery and chemotherapy were permitted after SMART. RESULTS: Mean age was 65.7 years (range, 36-85), induction FOLFIRINOX was common (81.7 %), most received elective coverage (57.4 %), and 34.6 % had surgery after SMART. Median FU was 22.9 months from diagnosis and 14.2 months from SMART, respectively. 2-year OS from diagnosis and SMART were 53.6 % and 40.5 %, respectively. Late grade ≥ 3 toxicity definitely, probably, or possibly attributed to SMART were observed in 0 %, 4.6 %, and 11.5 % patients, respectively. CONCLUSIONS: Long-term outcomes from the phase 2 SMART trial demonstrate encouraging OS and limited severe toxicity. Additional prospective evaluation of this novel strategy is warranted.
引用
- Chuong MD, Lee P, Low DA, et al. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study. Radiother Oncol. 2023. PMID: 38135187. doi:10.1016/j.radonc.2023.110064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。